Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05383209 · ClinicalTrials.gov registry record · Phase 2
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
A Phase 2 study, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT05383209: Completed Phase 2 study, sponsored by EyePoint Pharmaceuticals.
NCT05383209 is a Phase 2 study that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 77 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05383209, a Phase 2 study, has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
Primary Outcome
The DRSS used to describe overall retinopathy severity as well as the change in severity over time in the study eye. Severity ranges from level 10 (diabetic retinopathy absent) to level 85 (advanced proliferative diabetic retinopathy (PDR): posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at Week 36 from baseline.
Interventions
- DRUG EYP-1901
- OTHER Sham IVT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 2 |
What the finished NCT05383209 record still lists
NCT05383209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which EYP-1901 is the first listed.
NCT05383209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05383209 about?
NCT05383209 is a clinical study titled "Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)". A prospective, randomized, double-masked study that evaluated the ocular efficacy and safety of two doses of the EYP-1901 intravitreal (IVT) insert compared to sham.
What is the current status of trial NCT05383209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2022-09-28. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05383209?
The interventions under investigation include: EYP-1901 (DRUG), Sham IVT (OTHER).
Who is sponsoring clinical trial NCT05383209?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05383209's enrollment target sits among peer trials
77 891st of 2000 higher than 1,108 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI